Our care and research: At Mark Hinds Optometrists and Ophthalmic Trials Australia, our team is committed to improving the lives of patients living with severe dry eye disease, ocular surface inflammation, and autoimmune-related eye disease through advanced clinical care, research, and innovation. One important area of focus is Sjögren’s related dry eye disease — a… Continue reading Advancing Care for Patients with Sjögren’s Related Dry Eye Disease
Advancing Care for Patients with Sjögren’s Related Dry Eye Disease
Tag: ophthalmic trials australia
Advancing Care for Patients with Ocular Graft-versus-Host Disease (oGVHD)
Our care and research: At Mark Hinds Optometrists and Ophthalmic Trials Australia (OTA), our team is committed to improving the lives of patients living with severe ocular surface disease through research, innovation, and compassionate clinical care. One area of increasing focus is ocular graft-versus-host disease (oGVHD) — a potentially debilitating complication that can occur following… Continue reading Advancing Care for Patients with Ocular Graft-versus-Host Disease (oGVHD)
Latest Dry Eye Trials for Autoimmune Disease
Recent clinical trials have focused on innovative eye drop treatments for dry eye disease, particularly in the context of autoimmune disorders. Here are five notable trials: These trials represent a diverse array of approaches, from receptor-specific treatments and anti-inflammatory agents to novel extracts and advanced formulations, all aimed at improving symptoms and quality of life… Continue reading Latest Dry Eye Trials for Autoimmune Disease
Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial
The Ocular Surface Volume 29, July 2023, Pages 537-546 Stephanie L. Watson, Lyndon W. Jones, Fiona Stapleton, Mark Hinds, Alison Ng, Jacqueline Tan, Yair Alster, Charles Bosworth, Omer Rafaeli, Venita DePuy, The CELESTIAL STUDY Group Over the past few years our own, Mark Hinds, with his team at Ophthalmic Trials Australia (www.ot-au.com) have been involved in the multi-centered investigation into the efficacy and safety of selenium sulfide ointment in the setting of meibomian gland dysfunction (MGD)… Continue reading Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial
The Association for Research in Vision and Ophthalmology (ARVO 2023) Publication
AZR-MD-001 restores gland gunction and improves signs and ocular symptoms of mebomian gland dysfunction (MGD) Posterboard#: B0072 Abstract Number: 5175 – B0072 AuthorBlock: Preeya Gupta1,2, Laura Elizabeth Downie3, Mark Hinds4, Yair Alster5, Charles Bosworth5 1Ophthalmology, Triangle Eye Consultants, Raleigh, North Carolina, United States; 2Ophthalmology, Tulane University, New Orleans, Louisiana, United States; 3Optometry and Vision Science, The University of Melbourne, Melbourne,… Continue reading The Association for Research in Vision and Ophthalmology (ARVO 2023) Publication
The Association for Research in Vision and Ophthalmology (ARVO 2023) – Publication.
AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis Posterboard#: B0026 Abstract Number: 5129 – B0026 AuthorBlock: Lisa Nijm1,2, Jennifer P. Craig3, Mark Hinds4, Yair Alster5, Charles Bosworth5 1Ophthalmology, Warrenville EyeCare & LASIK, Chicago, Illinois, United States; 2Ophthalmology, University of illinois Eye and Ear Infirmary, Chicago,… Continue reading The Association for Research in Vision and Ophthalmology (ARVO 2023) – Publication.